METHOD OF DERIVING PROGENITOR CELL LINE

• US 20110008298A1
• Filed: 09/23/2010
• Published: 01/13/2011
• Est. Priority Date: 09/02/2005
• Status: Abandoned Application

• Current Assignee: Agency For Science Technology and Research
• Original Assignee: Agency For Science Technology and Research
• Inventors: Lye, Elias, Lim, Sai Kiang
• Application Number:
  US12/888,724
• Publication Number:
  US 20110008298A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/734 Proteases (EC 3.4.)
• CPC Class Codes: C12N 2502/1352 Mesenchymal stem cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0603 Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies
• CPC Class Codes: C12N 5/0662 Stem cells
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: G01N 33/5044 involving specific cell types

Abstract

We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.

Claims

1. A method of deriving a mesenchymal progenitor cell line from a parental embryonic stem cell, wherein the mesenchymal progenitor cell line comprises mesenchymal stem cells, the method comprising:

(a) providing the parental embryonic stem cell or descendents of the parental embryonic stem cell obtained by dispersing an embryonic stem cell colony with trypsin;

(b) culturing the parental embryonic stem cell in the absence of feeder cells in conditions that promote growth of putative mesenchymal progenitor cells and at least retard growth or propagation of embryonic stem cells;

(c) selecting mesenchymal progenitor cells which self-renew; and

(d) establishing in the absence of transformation a mesenchymal progenitor cell line from the mesenchymal progenitor cells which self-renew;

wherein the mesenchymal progenitor cell line is lineage restricted compared to the parental embryonic stem cell.

2. The method of claim 1, further comprising the step of deriving a differentiated cell from the mesenchymal progenitor cell line.

3. The method of claim 1, further comprising (a) performing the method in the presence of a candidate molecule;

and (b) determining an effect of the candidate molecule on the mesenchymal progenitor cell line.

4. A method according to claim 1, further comprising the step of using the progenitor cell line for the treatment of at least one of a disease treatable by regenerative therapy, cardiac failure, bone marrow disease, skin disease, burns, or a degenerative disease.

6. The method according to claim 2, further comprising the step of using the differentiated cell for the treatment of at least one of a disease treatable by regenerative therapy, cardiac failure, bone marrow disease, skin disease, burns, or a degenerative disease.

7. The method according to claim 1, further comprising the step of using the mesenchymal progenitor cell line to prepare a pharmaceutical composition for the treatment of at least one of a disease treatable by regenerative therapy, cardiac failure, bone marrow disease, skin disease, burns, or a degenerative disease.

8. The method according to claim 2, further comprising the step of using the differentiated cell to prepare a pharmaceutical composition for the treatment of at least one of a disease treatable by regenerative therapy, cardiac failure, bone marrow disease, skin disease, burns, or a degenerative disease.

9. The method according to claim 4, wherein the degenerative disease is at least one of diabetes, Alzheimer'"'"'s Disease, Parkinson'"'"'s Disease, or cancer.

10. The method according to claim 6, wherein the degenerative disease is at least one of diabetes, Alzheimer'"'"'s Disease, Parkinson'"'"'s Disease, or cancer.

11. The method according to claim 7, wherein the degenerative disease is at least one of diabetes, Alzheimer'"'"'s Disease, Parkinson'"'"'s Disease, or cancer.

12. The method according to claim 8, wherein the degenerative disease is at least one of diabetes, Alzheimer'"'"'s Disease, Parkinson'"'"'s Disease, or cancer.

5. A differentiated cell produced by:

(a) providing a parental embryonic stem cell or descendents of the parental embryonic stem cell obtained by dispersing an embryonic stem cell colony with trypsin;

(b) culturing the parental embryonic stem cell in the absence of feeder cells in conditions that promote growth of putative progenitor cells and at least retard growth or propagation of embryonic stem cells;

(c) selecting progenitor cells which self-renew;

(d) establishing in the absence of transformation a progenitor cell line from the progenitor cells which self-renew, and

(e) deriving a differentiated cell from the progenitor cell line,

wherein the progenitor cell line is lineage restricted compared to the parental embryonic stem cell.